Background: Once daily dosing (ODD) of aminoglycosides has become a standard of care for most patient populations. However, the use of ODD of aminoglycosides has not been clarified in febrile neutropenia.
Introduction
Aminoglycosides are one of the oldest classes of antimicrobials. Although generally effective, they have an undesirable toxicity profile, which has reduced their clinical utility over the years. However, the recent emergence of resistant Gram-negative bacteria, in conjunction with an improved safety profile of the aminoglycosides through once daily dosing (ODD), has revived the interest in the clinical utility of these antibiotics.
1,2 ODD has been proven to be as effective as multiple daily dosing (MDD), with a reduced risk of nephrotoxicity, in various clinical settings. 3 -12 In fact, ODD of aminoglycosides has become a standard of care in almost all settings; exceptions include pregnant women and patients with febrile neutropenia or endocarditis. 3, 4, 13 Nowadays, the aminoglycosides are not used in febrile neutropenia as much as in the recent past. The 2002 Infectious Diseases Society of America (IDSA) recommendations included aminoglycosides in conjunction with a b-lactam and/or vancomycin for high-risk patients. 14 However, the most recent meta-analysis concluded that b-lactam monotherapy is preferable to b-lactam+aminoglycoside combination therapy in the empirical treatment of febrile neutropenia in almost all cases. The only exception is patients with documented bacteraemia and profound (,100 neutrophils/mL) or prolonged neutropenia. 15 Thus, current guidelines from the European Society for Medical Oncology (ESMO, 2010) suggest that aminoglycosides are administered only in patients at high risk for prolonged neutropenia and those with bacteraemia, in combination with a b-lactam antibiotic. 16 Yet, several institutional protocols still suggest that treatment of a patient with febrile neutropenia should consist of both a b-lactam and an aminoglycoside.
A previous meta-analysis suggested that ODD administration may be as effective as MDD in immunocompromised patients, but underlined the necessity for additional studies. 11 However, that meta-analysis, published in 1997, included only four trials (811 patient-episodes, not fulfilling the definition criteria of febrile neutropenia), two of which (631 patient-episodes) had assigned a different b-lactam antibiotic in each treatment arm, which could disproportionately affect the effectiveness outcomes. In this context, we sought to systematically review the existing evidence regarding the effectiveness and safety of ODD versus MDD of aminoglycosides in patients with febrile neutropenia, using the methodology of meta-analysis.
Methods

Data sources
We searched PubMed, Scopus, Cochrane Central Register of Trials and clinicaltrials.gov to identify relevant trials for the meta-analysis. The primary search was conducted with the following pattern: (neutropeni*) AND (fever OR febrile) AND (aminoglycoside* OR gentamicin OR tobramycin OR netilmicin OR amikacin). We set no restriction in the year of publication. We also sought to find potentially useful studies in the references of the relevant articles. The search process took place in July 2010.
Study selection
Two investigators (M. N. M. and K. A. P.) independently searched the literature and examined relevant studies for potential inclusion in this meta-analysis. To be considered eligible, a study should be a randomized controlled trial (RCT) that examines the effectiveness and/or safety of ODD administration of aminoglycosides in comparison with MDD for the treatment of patients with febrile neutropenia. Additional antimicrobial agents could be used in the trials. We considered eligible studies written in English, French, Spanish, German, Italian or Greek. Unpublished studies reported as abstracts in conferences were not included in this review. 17 
Data extraction
We extracted data regarding the clinical setting, patient population, number of patients [by intention to treat (ITT), and those clinically and microbiologically assessed], antimicrobial agents and doses used, clinical and microbiological outcomes, safety, and mortality. The ITT population comprised patients who received at least one dose of the study medications. The clinically evaluable (CE) population comprised patients that appropriately completed the treatment protocol, had complete follow-up and for whom full data on treatment outcomes were available. The microbiologically evaluable (ME) population was a subset of the CE population, whose infections were also documented microbiologically.
Two reviewers (M. N. M. and K. A. P.) independently extracted the relevant data. Any disagreement was resolved by consensus in meetings with all investigators. When information on the primary outcomes was not reported, we contacted the corresponding authors asking for additional data.
We also performed a quality review of each trial regarding details of randomization, generation of random numbers, details of doubleblinding procedure, information on withdrawals and allocation concealment. One point was awarded for the specification of each criterion, with a maximum score of 5. Trials with a score of ≥3 were considered of high-quality, whereas trials that scored ≤2 points were considered of low-quality, according to a modified Jadad score. 
Analysed outcomes
The primary outcome measures for this meta-analysis were treatment success (defined as resolution of the episode of neutropenic fever without requiring any modification on the assigned antibacterial regimen, except for adjustments of the aminoglycoside dose, in the ITT and CE population), 19 nephrotoxicity (defined as a .50% or a .45 mmol/L increase in serum creatinine above the pre-treatment baseline, in the ITT population) and all-cause mortality (during treatment and follow-up, in the ITT population).
Secondary outcomes included treatment success in the ME population and ototoxicity (assessed either clinically or with audiometry or otoacoustic emissions, in the ITT population).
For the analysis of treatment effectiveness and all-cause mortality, we considered eligible only the trials where the supplementary b-lactam of the treatment protocol (in addition to the aminoglycoside) was identical in both arms. For the analysis of treatment safety (nephrotoxicity and ototoxicity), trials with a different supplementary b-lactam in each arm were also considered eligible, since b-lactams are known not to cause considerable adverse events in the kidney (except for occasional interstitial nephritis) or inner ear.
Data analysis and statistical methods
We performed the statistical analyses with Review Manager (RevMan) (computer program), version 5.0 (Copenhagen: the Nordic Cochrane Centre, the Cochrane Collaboration, 2008). We assessed the heterogeneity between trials by using a x 2 test (P,0.10 was defined to indicate significant heterogeneity) or I 2 . We did not assess publication bias due to the small number of included trials. 20 Pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all primary and secondary outcomes were calculated by the Mantel-Haenszel fixed effects model (FEM) or the DerSimonian -Laird random effects model (REM). 21, 22 For all analyses, we presented results from the FEM only when there was no significant heterogeneity between trials; otherwise, results from the REM are presented.
Results
We identified a total of nine RCTs (enrolling 2125 patientepisodes) comparing the outcomes of ODD versus MDD administration of aminoglycosides for the treatment of patients with febrile neutropenia. 23 -31 The selection process is depicted in Figure 1 . In six RCTs, both arms were treated with the same supplementary b-lactam;
26 -31 five of those reported effectiveness and mortality data, and thus only five RCTs (enrolling 568 patient-episodes; Table 1 ) were eligible for the effectiveness and mortality analyses. 26,28 -31 For the safety analysis, eight RCTs (enrolling 2023 patient-episodes) 23 -25,27 -31 reported relevant data and were considered eligible (one trial was excluded due to inconsistent definitions 26 ).
Systematic review
Characteristics of RCTs
The main characteristics of the included trials are presented in Table 1 . The mean quality score of the analysed trials for the effectiveness and mortality analyses was 3 (range: 2 -5) [for the safety analysis, 2.6 (range: 1 -5)]. Two RCTs enrolled only paediatric patients (113 patient-episodes) 29, 30 and another two enrolled only adult patients (245 patient-episodes) 26, 28 [four RCTs only paediatric (772 patient-episodes) 24, 25, 29, 30 and two RCTs only adult patients (183 patient-episodes) 27, 28 for the safety analysis]. Tobramycin was administered in two trials (270 patient-episodes), 30, 31 netilmicin in two trials (245 patientepisodes) 26, 28 and amikacin in one trial (53 patient-episodes) 29 [for the safety analysis, tobramycin in two trials (270 patientepisodes), 30, 31 netilmicin in one trial (143 patient-episodes) 28 and amikacin in five trials (1610 patient-episodes) 23 -25,27,29 ]. The extracted outcome data from the included RCTs are presented in Table 2 . We used the FEM for all analyses, due to the low heterogeneity of the included trials (P .0.10).
Out of the five trials pooled for the effectiveness analysis, patients did not fulfil the criteria of febrile neutropenia definition in one study; in that study, patients were described as 'immunocompromised with suspected sepsis and rectal temperature of ≥38.58C'. For that study, we only extracted data referring to patients with an ANC ,1000/mm 3 for the effectiveness analysis; since no such data were available for the mortality and safety analyses, this trial was excluded. 26 Out of the eight trials pooled for the safety analysis, five enrolled patients fulfilling all criteria of febrile neutropenia, 25,28 -31 two trials enrolled patients with ,1000 neutrophils/mm 323, 24 and one study just stated that patients with febrile neutropenia were included. 27 Most studies had excluded patients with known allergy to one of the protocol antibiotics (five of nine trials), 23, 26, 28, 30, 31 previous aminoglycoside treatment (in general, during the last 2 weeks before enrolment, six of nine trials) 24 -26,28,30,31 and previous antibacterial treatment (in general, during the last 2 days before enrolment, seven of nine studies). 23 -26,28,29,31 With regard to the enrolled patients' renal function, seven out of nine trials reported to have excluded patients with abnormal renal function. 23,25 -29,31 The most common exclusion criterion was a high serum creatinine concentration (.120 mmol/L in three trials 28, 29, 31 and .300 -350 mmol/L in two trials 23, 26 ), followed by a calculated creatinine clearance of ,30 mL/min/1.73 m 2 (two trials 25, 27 ). Three trials did not enrol patients with known decreased auditory or vestibular function 26, 28, 31 and four trials used pregnancy/nursing as an exclusion criterion. 23, 26, 28, 31 Out of the seven trials that reported eligible nephrotoxicity data, four defined nephrotoxicity as an increase in serum creatinine ≥50% above the pre-treatment baseline, 24, 28, 29, 31 another two defined it as an increase of .45 mmol/L 23,27 and the remaining trial included both definitions (either of the two was valid). 25 Out of the six trials that reported eligible ototoxicity data, three assessed the patients clinically, 24, 28, 31 and the remaining three assessed the patients both clinically and with audiometry (ototoxicity defined as a measure of ≥15 -20 dB worse than baseline in any frequency). 23, 25, 30 Effectiveness and mortality analyses
The pooled data for the CE population (five RCTs, 403 patientepisodes; Figure 2) Articles assessed for eligibility after screening of title and abstract: 114
Articles However, treatment success for the ME population (three RCTs, 119 patient-episodes; Figure 2) Complete data on all-cause mortality were reported in only four of the eligible RCTs (403 patient-episodes; Figure 3 ), indicating no difference between the compared regimens. 28 -31 The pooled RR was 0.77 (95% CI: 0.21, 2.78) for the ITT population. There was also no difference in the treatment duration between the ODD and the MDD arms. Last, we performed a sensitivity analysis regarding the treatment success in the CE population. We observed that high-quality RCTs 28 
Safety analysis
Nephrotoxicity data were extracted from seven RCTs (1643 patient-episodes; Figure 4) . 23 -25,27 -29,31 Three RCTs had excluded the patients who had been treated with other potentially nephrotoxic agents, 24, 28, 31 one trial reported data on all patients, as well as the subset that received such agents separately (for that study, we extracted data on the patients that did not receive other nephrotoxic agents), 23 two trials 25, 27 enrolled patients receiving such medications, but reported an equal distribution in both arms, and the remaining trial did not specify. 29 The pooled RR for nephrotoxicity was 0.74 (95% CI: 0.36, 1.50), indicating no significant difference between the ODD and MDD regimens.
In order to assess the potential influence of the administration of additional nephrotoxic agents in our findings, we performed an exploratory analysis. We evaluated separately the trials excluding 23, 24, 28, 31 or including 23, 25, 27 patients who had received additional nephrotoxic agents, but we found no difference between the ODD and MDD regimens in either analysis [pooled RR: 0.62 (95% CI: 0.27, 1.40) and 1.43 (95% CI: 0.67, 3.05), respectively]. We also performed a sensitivity analysis for nephrotoxicity and observed no difference; high-quality Ototoxicity data were extracted from six RCTs (862 patientepisodes; Figure 4) . 23 -25,28,30,31 The pooled RR of the six trials was 1.05 (95% CI: 0.51, 2.19). Three of the trials (466 patientepisodes) 24, 28, 31 reported no ototoxicity at all. One study reported that some patients had also received other ototoxic agents; 23 out of the patients not having received such agents, three (ODD) versus four (MDD) patients developed ototoxicity (no further details were provided).
Discussion
Our findings suggest that ODD administration of aminoglycosides for the treatment of patients with febrile neutropenia is at least as effective and as safe as MDD administration, in combination with a b-lactam. This is in concordance with the findings of previous studies; 3 -12 most meta-analyses have observed a trend towards better effectiveness of the ODD regimen in the CE population, and no difference in the ME or ITT population, in mainly immunocompetent populations. Taking into consideration a meta-analysis suggesting that aminoglycosides should only be used in neutropenic febrile patients with profound or prolonged neutropenia, 15 it would be particularly important to focus on this subset of patients; however, none of the trials we identified provided relevant data.
Aminoglycosides exhibit concentration-dependent activity against the bacteria. 32 -34 In addition, this class of antibiotics exerts the post-antibiotic effect (PAE), which implies the suppression of bacterial growth even when the serum levels of the antibiotic drop below the MIC; 35 an effect that is probably attributed to the irreversible binding of the aminoglycoside to the 30S subunit of the bacterial ribosome. 36 Therefore, the faster achievement of high peak concentrations through ODD administration may be beneficial, especially since an optimal peak serum concentration early during the treatment has been shown to correlate with a favourable clinical outcome. 33, 34, 37 In theory, the extended-interval administration of aminoglycosides through ODD exhibits several additional advantages, such as attenuated emergence of resistant bacterial strains, reduced nephrotoxicity and decreased cost of treatment. The early high peak serum drug concentrations in conjunction with the extended drug-free interval help to reduce the first-exposure Systematic review effect and overcome the onset of adaptive resistance of the bacteria. 38 Furthermore, the increased drug-free interval allows for a safer drug clearance profile, since it results in decreased accumulation of the drug in the proximal tubules. 39 -41 Although our study, in addition to most of the other relevant studies, found no difference in the incidence of nephrotoxicity, it may be possible that such an effect would be evident in patients with baseline impaired renal function (most RCTs excluded such patients from enrolment). Last, the ODD regimen is indisputably preferable in terms of cost of treatment, since it requires less frequent administration and serum concentration monitoring. 24, 42 It has been debated whether the PAE of the aminoglycosides is sufficient for ODD in neutropenic subjects. 43 In animal models, the duration of the PAE of aminoglycosides in neutropenic animal hosts was attenuated, when compared with that of normal hosts. 35,44 -46 However, when extended-interval aminoglycosides were combined with a b-lactam in neutropenic animal hosts, owing to the in vivo synergism, the ODD regimen was at least as effective as the MDD. 45, 47 Aminoglycosides are nowadays only used in combination with a b-lactam in neutropenic patients, which may be the factor accounting for the (at least) similar effectiveness of the ODD with the MDD regimen, despite the supposedly attenuated PAE. Our study has certain limitations, which should be considered in its interpretation. First, the populations of the included trials were not completely homogenous (as stated above, five out of nine trials enrolled patients with an ANC of ,500/mm 3 , three trials enrolled patients with ,1000 neutrophils/mm 3 and the remaining trial did not specify; nephrotoxicity was defined as an increase in serum creatinine ≥50% in four trials, an increase of .45 mmol/L in another two and either of the two in the remaining trial). Moreover, due to the small number of included trials, the assessment of publication bias by Egger's funnel plot method would not be accurate and potentially significant effects of ODD might not be evident due to the relatively small sample size. In addition, the potentially advanced virulence of the contemporary multidrug-resistant bacteria may pose a challenge in the adaptation of our findings in the present setting, Systematic review since some of the trials were conducted more than a decade ago. Last, our review suffers the inherent limitations posed by the methodology of meta-analysis. 48 In conclusion, this meta-analysis shows that ODD of aminoglycosides is at least as effective as MDD in patients with febrile neutropenia (there was a trend towards better effectiveness of the ODD only in the CE population). With regard to safety, ODD appears to be no more toxic than MDD. RCTs comparing the outcomes of ODD versus MDD in patients with bacteraemia and profound or prolonged neutropenia would be of particular importance to enrich our knowledge on this specific patient population.
